{"groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"FG000","title":"Pemigatinib 13.5 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"17"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Moved to Commercial Supply of Investigational Drug"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Received First Dose of Chemotherapy for Stem Cell Transplant"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Sponsor's Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study was conducted at 21 study centers in Belgium, Canada, France, Germany, Italy, Japan, Spain, United Kingdom, and the United States."}